Jiangsu Hengrui Medicine and TG Therapeutics’ Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program

Ambrogio Visconti

Goodwin advised Jiangsu Hengrui Medicine as it entered into an exclusive global license agreement with TG Therapeutics. Under the terms of the agreement, Jiangsu Hengrui will…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here